RPL12P22

Across TCGA pan-cancer cohorts, RPL12P22 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL12P22’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL12P22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL12P22 is over-expressed in tumor.

BRCA and KICH are the cancer types where RPL12P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL12P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	+0.024	.049	2	view →
KICH	All	II,III,IV	+0.046	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RPL12P22–BRCA

Open the BRCA breakdown →